However, the 4‐year DFS rate of adjuvant osimertinib for EGFR‐mutated stage II–IIIA NSCLC is only 70%, and the presence of common EGFR mutations alone is still not a sufficient biomarker for adjuvant EGFR‐TKI. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.